Exhibit 99.1

                      EDG CAPITAL, INC ANNOUNCES FILING OF
                  INVESTIGATIONAL NEW DRUG APPLICATION WITH FDA

(Garden City, NY --- June 5, 2001) --- EDG Capital, Inc. (OTCBB: EDGN), a
developer of nuclear pharmaceuticals for therapeutic use in the treatment of
cancer, announced today that, on June 4, 2001, its wholly owned subsidiary
Isotope Solutions, Inc. (ISI) filed an Investigational New Drug (IND)
application with the Food and Drug Administration. The application requests
permission to begin testing ISI's Radioactive Cisplatin technology in patients
with liver cancer. Medical research groups managed by ISI will be conducting the
testing.

"This is a major milestone in the development of this exciting new technology,"
said Jack Schwartzberg, Chief Executive Officer, President and Chairman of EDG
Capital. "We are ready to begin testing this technology in liver cancer patients
as soon as we get clearance from the FDA," he added.

The radioactive cisplatin used in ISI's Radioactive Cisplatin technology,
195mPt-Cisplatin, is chemically identical to standard cisplatin except that the
platinum it contains has been made radioactive. Standard cisplatin is an
effective and widely used chemotherapeutic agent for the treatment of various
types of cancers. Cisplatin contains the element platinum and works by binding
with tumor cell DNA, thereby disrupting its reproduction. Radioactive Cisplatin
is designed to deliver high doses of radioactivity directly into the tumor
cells.

It is well established that directed radiation can kill tumor cells effectively.
In fact, many types of cancers are treated by external beam radiation and
interstitial seed brachytherapy implants. Unfortunately, these radiation
techniques are often unable to deliver therapeutic doses to the tumor without
damaging surrounding normal tissues. Radioactive Cisplatin will take advantage
of cisplatin's ability to bind directly to tumor cell DNA and deliver intense,
localized radiation within solid tumors. This in turn should minimize injury to
surrounding tissues and organs.

"Radioactive Cisplatin represents the next step forward in the platinum-based
treatment of cancers," continued Mr. Schwartzberg. " Our Radioactive Cisplatin
may find future application in the treatment many types of cancers, including
liver, bladder, lung, brain, gastric, head and neck, pancreatic, esophageal,
gynecological, breast, colon and prostate. By enhancing cisplatin's already
well-recognized effectiveness with targeted tumor-destroying radiation, we hope
to improve substantially the current treatment of many cancers."

About EDG Capital, Inc. Through its wholly-owned subsidiary, Isotope Solutions,
Inc., EDG Capital is engaged in the research, development and testing of nuclear
pharmaceuticals for therapeutic use in the treatment of the most lethal forms of
cancer. Internationally renowned clinicians, who are under management contracts
with Isotope Solutions Inc., conduct research for the company.

Legal Disclaimers: This press release may contain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual performance and
results of operations may differ materially from those projected or suggested in
the forward-looking statements. The forward-looking statements contained herein
represent EDG Capital, Inc.'s judgment as of the date of this release, and EDG
Capital, Inc. cautions investors not to place undue reliance on such statements.


                                       3


CONTACT:    EDG Capital, Inc., New York
            Shragie David Aranoff
            Vice President
            516/222-5154
            shragie@isotopesolutions.com

            or

            Rubenstein Associates, Inc.
            Patricia Amerman
            Vice President
            212/843-8049
            pamerm@rubenstein.com


                                       4